Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Dana Farber Cancer Institute, Boston, Massachusetts Mayo Clinic, Rochester, Minnesota University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center), Rochester, New York University of Washington-Seattle Cancer Care Alliance, Seattle, Washington France
CHU d'Amiens-Picardie - Hopital SUD, Amiens Italy
University of Bologna, Bologna IRCCS Policlinico San Matteo Foundation - University of Pavia, Naples IRCCS Policlinico San Matteo Foundation - University of Pavia, Pavia Spain
University Hospital Vall d'Hebron, Institute of Oncology, Barcelona Clinica Universidad de Navarra, Madrid Clinica Universidad de Navarra, Pamplona Hospital Clinico Universitario de Salamanca, Salamanca